Showing results (2381-2390 of 2,553) with videos related to
Sort By:
Pageof 256
NPJ Digital Medicine|June 25, 2026
Spatially identifying regions of tumor recurrence in patients with suspected recurrent glioma using physiologic MRI and machine learningJacob Ellison, Nate Tran, Tracy L Luks, et al.Acta Neuropathologica|May 16, 2015
Dysregulation of locus coeruleus development in congenital central hypoventilation syndromeHiroko Nobuta, Maria Roberta Cilio, Olivier Danhaive, et al.European Journal of Nuclear Medicine and Molecular Imaging|January 6, 2025
Joint EANM/EANO/RANO/SNMMI practice guideline/procedure standard for PET imaging of brain metastases: version 1.0Antoine Verger, Nelleke Tolboom, Francesco Cicone, et al.The Lancet. Oncology|April 9, 2011
Response assessment in neuro-oncology (a report of the RANO group): assessment of outcome in trials of diffuse low-grade gliomasM J van den Bent, J S Wefel, D Schiff, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 17, 2008
Phase II study of erlotinib plus temozolomide during and after radiation therapy in patients with newly diagnosed glioblastoma multiforme or gliosarcomaMichael D Prados, Susan M Chang, Nicholas Butowski, et al.Cancer|April 27, 2021
Loneliness and symptom burden in oncology patients during the COVID-19 pandemicChristine Miaskowski, Steven M Paul, Karin Snowberg, et al.Neuro-Oncology|April 10, 2024
Liquid biopsy for improving diagnosis and monitoring of CNS lymphomas: A RANO reviewLakshmi Nayak, Chetan Bettegowda, Florian Scherer, et al.Neuro-Oncology|August 5, 2011
Is surgery at progression a prognostic marker for improved 6-month progression-free survival or overall survival for patients with recurrent glioblastoma?Jennifer L Clarke, Michele M Ennis, W K Alfred Yung, et al.Journal of Neuro-Oncology|June 30, 2009
Phase II trials of erlotinib or gefitinib in patients with recurrent meningiomaAndrew D Norden, Jeffrey J Raizer, Lauren E Abrey, et al.Neuro-Oncology|February 12, 2011
Clinical trial end points for high-grade glioma: the evolving landscapeDavid A Reardon, Evanthia Galanis, John F DeGroot, et al.Pageof 256